Increase Oversight on Cooperative Group Trials

E. Yepes, B. McGough, F. Covington, M. Wong, A. Mesidor, F. Hsu, M. Huber, A. Joshi, B. Pothuri, J. Mehnert

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

1. Background
The Perlmutter Cancer Center (PCC) at NYU Langone Health conducts and oversees approximately 475 trials, 30 percent of which are National Cancer Institute (NCI) cooperative group trials. Data quality and regulatory oversight of cooperative group trials can be challenging due to limited monitoring compared to industry-sponsored trials. Most cooperative trials do not have routine monitoring but instead audits are conducted every 1-3 years depending on the cooperative group and prior audit results. Given the lack of oversight, compliance is a concern and preparation for these infrequent audits can be burdensome. Prior to 2020, Perlmutter Cancer Center (PCC) had an increase in major findings and received an “Unacceptable” on one of the audits. Additionally, there was deficiency in timely data entry and resolution. The Clinical Trials Office (CTO) set to establish a better oversight management plan.

2. Goals
• Overall improvement in quality and timeliness of data entry and regulatory document(s) submissions
• Periodic internal monitoring of cooperative group trials
• Implement preventive measures to reduce future major/minor regulatory and data audit findings
• Increase oversight of cooperative group trials

3. Solutions and Methods
• In 2022, the Quality Assurance Unit (QAU) was approved for two new Quality Assurance (QA) Specialists to support quarterly monitoring of cooperative group trials
  • The QA specialists also confirm the current amendment activated at PCC is up to date and will email the Regulatory team and management if there is a discrepancy
• Regulatory specialists are required to review the Cancer Trials Support Unit (CTSU) every two weeks for amendments and new information and update a tracker
  • PCC initiated monthly meetings to review all accruals, data, and regulatory activities for all cooperative group trials with any activity at PCC and affiliated sites
• Semi-monthly CTSU Data Delinquency reports are sent to the data coordination unit requesting resolutions/updates

4. Outcomes
In 2023, there was a 58 percent decrease in data delinquency and 79 percent decrease in regulatory major findings. As a result of the implemented initiatives, there is a decrease in late protocol-related submissions. We received “Acceptable” reviews on all audits since 2020. Internal auditing has significantly improved regulatory compliance by a decrease of 130 major findings in 2022 to 16 in 2023. Data entry quality and timeliness has improved by 52 percent due to the bi-monthly CTSU delinquency reports submissions to the data team and monthly meetings. In 2022, we joined ETCTN, adding another cooperative group to our portfolio, which increased our cooperative group accruals by 100 percent, from 2020 to 2023, which makes higher compliance even more remarkable. We were also approved to
become an NRG Main Member in 2023 and recently received an ECOG commendation on the 2023 ECOG-ACRIN Institution Evaluation.

5. Lessons Learned and Future Directions
Increased oversight, including active monitoring, is necessary to ensure compliance with cooperative group trials. The addition of cooperative group QA specialists, monthly meetings and trackers have been instrumental in our success. Looking ahead, with continued commitment to these workflows, we want to focus on getting our data quality above 90 percent within query resolution and data accuracy for all our cooperative group trials and continue to decrease regulatory findings.